Ivacaftor
Ivacaftor (Kalydeco) treats cystic fibrosis (CF) by helping a faulty CFTR chloride channel open. It works only when the CFTR protein reaches the cell surface and responds to the drug, so whether someone can benefit depends on which CFTR variants cause their CF. The FDA label limits ivacaftor to people with at least one responsive variant, such as G551D, and CPIC recommends against it for people without one. Gene2Rx reports do not assess CFTR; this page explains the guidance for reference.
| Brand names | Kalydeco; ivacaftor is also part of combination CF medicines |
|---|---|
| Used for | Cystic fibrosis in people 1 month and older with at least one ivacaftor-responsive CFTR variant |
| Genes | CFTR |
| Guidance | CPIC guideline (2014), level A [1]; FDA label, testing required [2] |
| Gene2Rx coverage | Not assessed. Gene2Rx reports do not include CFTR or ivacaftor. |
How ivacaftor works
CF is an inherited disease caused by variants in both copies of the CFTR gene. CFTR is a channel that moves chloride and bicarbonate across the surface of cells in the airways, intestines, pancreas, sweat glands and other tissues. When it fails, the liquid layer lining the airways dries out, mucus builds up and is not cleared, and infection and inflammation follow [1].
Ivacaftor is a CFTR "potentiator": it increases the time the channel spends open (its gating). The amount of chloride it can move depends on how much CFTR protein reaches the cell surface and how well a particular mutant protein responds [2]. Before ivacaftor, CF treatments addressed only the effects of the faulty channel; ivacaftor was the first approved drug aimed at a specific CFTR defect [1].
The adult dose is 150 mg every 12 hours with fat-containing food, with granules for young children dosed by age and weight. Ivacaftor is broken down mainly by CYP3A and has a half-life of about 12 hours. The label calls for liver enzyme tests before and during treatment, and eye examinations in children because of reports of cataracts [2].
How CFTR variants affect ivacaftor
About 1,900 disease-causing CFTR variants had been described when CPIC wrote its guideline, and they fall into classes by what goes wrong: too little protein made, protein misfolded and destroyed before it reaches the surface, protein at the surface that does not open properly (a gating defect), and others [1].
Ivacaftor can only help a protein that is at the cell surface. G551D (rs75527207) is the classic example: the protein reaches the surface but does not open normally, and ivacaftor restores much of its function. G551D is the third most common CF variant and was found in 4.4% of people with CF in the registry data CPIC cites. In two randomized trials in people with at least one G551D variant, ivacaftor improved lung function (FEV1) by more than 10% from baseline, and the larger trial showed lasting gains in weight, symptoms and fewer flare-ups over 48 weeks [1].
F508del, the most common CF variant, works differently. The protein misfolds and is destroyed before reaching the surface, so ivacaftor alone has little to act on. A trial in people with two copies of F508del showed no benefit from ivacaftor alone, although it was not powered to test efficacy [1]. Combination medicines that add a "corrector" to move F508del protein to the surface were developed for this reason.
Since the original guideline, the list of responsive variants has grown. The current label covers variants shown to respond in clinical or laboratory data [2], and CPIC's CFTR allele table now lists 103 variants as "ivacaftor responsive," including G551D, R117H and several splicing variants; any other CFTR sequence is classed as non-responsive [3].
What the guidelines recommend
CPIC published its ivacaftor guideline in 2014, when the drug was approved only for G551D [1]. The pair is CPIC level A, its highest level: genetic information should be used to change prescribing. CPIC's gene-drug list also records that the FDA label requires testing [4]. The Kalydeco label says that if a patient's genotype is unknown, an FDA-cleared CF mutation test should be used, with confirmation by sequencing when the test's instructions call for it [2].
| Result | What it means | Guideline recommendation |
|---|---|---|
| Ivacaftor responsive | At least one responsive variant, such as G551D. In trials, significant improvement in lung function, weight, flare-up risk, symptoms and sweat chloride. | Use ivacaftor according to the product label. Strong recommendation. |
| Ivacaftor non-responsive | No responsive variant, for example two copies of F508del. No meaningful change in sweat chloride, lung function, flare-ups or weight; unlikely to respond. | Ivacaftor is not recommended. Moderate recommendation. |
| Ivacaftor irrelevant or not available | A result that does not bear on ivacaftor treatment, or no CFTR result. | No genotype-based recommendation. |
CPIC's recommendations covered people 6 and older because that was the age range studied at the time [1]; the current label extends treatment to infants from 1 month [2].
Want to know what your genetics say about how you'll respond to Ivacaftor?
A Gene2Rx report reads your own DNA to show how it may affect your response to Ivacaftor and your other medications.
Using a CFTR result
Decisions about ivacaftor belong with a CF care team, using a clinical CFTR test. CPIC advises that people discuss their CFTR results with a CF physician or genetic counselor [1]. Do not start, stop or change a CF medicine because of a genetic result without talking to your CF team.
Drug interactions affect the dose. Strong and moderate CYP3A inhibitors raise ivacaftor levels, and the label lowers the dose for people taking them (for those 6 and older, 150 mg twice a week with a strong inhibitor or 150 mg once a day with a moderate one) and does not recommend them under 6 months of age. Food or drink containing grapefruit should be avoided [2].
CFTR results also matter to relatives. CF is recessive, about 1 in 30 people in the US carry a CF variant, and two carrier parents have a 25% chance of having a child with CF in each pregnancy. CPIC notes that genetic counseling is important for families [1].
What Gene2Rx cannot tell you
Gene2Rx does not call CFTR variants and does not include ivacaftor in its reports. Consumer arrays read a limited set of fixed positions, and CF is caused by hundreds of different variants, so an uploaded file cannot establish whether someone has CF, is a carrier, or carries a responsive variant. The Kalydeco label requires an FDA-cleared CF mutation test for this purpose [2].
Even with a responsive variant, response varies. CPIC notes that some people with G551D do not respond, that sweat chloride changes did not track clinical benefit in the trials, and that the second CFTR variant a person carries may affect how well the drug works [1].
Common questions
Can my 23andMe or AncestryDNA data tell me if ivacaftor will work?
No. Gene2Rx does not analyze CFTR, and eligibility depends on a clinical CFTR test, as the label requires.
I have two copies of F508del. Is ivacaftor useless for me?
Ivacaftor alone did not help people with two F508del copies, and CPIC does not recommend it alone for them. Combination medicines that include ivacaftor were developed for F508del; your CF team can advise which applies.
Sources and further reading
- Clancy JP, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype. Clin Pharmacol Ther (2014). CFTR biology, trial evidence and recommendations.
- Kalydeco (ivacaftor) tablets and oral granules: prescribing information (Vertex). DailyMed. Indication, testing requirement, dosing and interactions.
- CPIC. CFTR allele functionality table (spreadsheet). Variants classed as ivacaftor responsive.
- CPIC. Gene-drug pairs and CPIC levels (spreadsheet). CFTR and ivacaftor: level A; FDA label testing required.
Genes that affect Ivacaftor
See the full list of drugs affected by each gene:
Brand names containing Ivacaftor
See how your genetics affect each product Ivacaftor shows up in:
Ivacaftor is also in 3 combination products, such as Trikafta, Symdeko, Orkambi. Guidance is written for ivacaftor on its own, so what your genes mean for a combination is less clear. See them all and how we handle combination products.
Interested in learning more about how your genetics may affect your response to medication? Get started with Gene2Rx today.
I'm Interested